Pharma major Lupin Ltd on Wednesday announced the launch of its generic version of anti-diabetic medication dapagliflozin and metformin hydrochloride extended-release tablets in the United States, following approval from the US Food and Drug Administration.

The company stated that the tablets are available in multiple strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg, as per its regulatory filing.

Lupin added that the launch comes after receiving approval for its abbreviated new drug application (ANDA), with the product deemed bioequivalent to Xigduo XR.